Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Johnson & Johnson ( JNJ)

ASCO presentation: Phase III study of Zytiga in "pre-chemo" prostate cancer patients.

What we already know: Zytiga significantly delayed tumor progression in prostate cancer patients who have not been treated with chemotherapy. Zytiga also helped these patients live longer, although the survival benefit was not statistically significant. Based on these positive results, independent data monitors stopped the study early.

Key questions: What was the magnitude of benefit provided by Zytiga? In particular, what does the survival benefit trend look like and might it become statistically significant on longer follow up?

Other notes: At this point, the Zytiga study is the biggest attention grabber at ASCO from a Wall Street perspective because the results have far-reaching impact not only on J&J but prostate cancer drug competitors Medivation ( MDVN) and Dendreon ( DNDN).

If you liked this article you might like

Insider Trading Alert - SUMR, CVO And ARQL Traded By Insiders

Insider Trading Alert - ARQL, MTSC And PFNX Traded By Insiders

Insider Trading Alert - SAVE, ARQL And THST Traded By Insiders

Insider Trading Alert - ORM, OLBK And ARQL Traded By Insiders

Insider Trading Alert - TIPT, RDNT And ARQL Traded By Insiders